Polaryx Therapeutics, Inc. Common Stock (PLYX) — Financial statements
Income statement, balance sheet, and cash flow for Polaryx Therapeutics, Inc. Common Stock — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Revenue & Gross Profit | ||||
| Revenue | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||
| R&D Expenses | 6↑122.9% | 3↑1.4% | 3 | |
| General & Administrative Expenses | 0.00↓100.0% | 2↑52.6% | 1 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 2↑0.9% | 2↑52.6% | 1 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 8↑79.7% | 4↑15.1% | 4 | |
| Total Costs & Expenses | 8↑79.7% | 4↑15.1% | 4 | |
| Operating Results | ||||
| Operating Income | -8↓79.7% | -4↓15.1% | -4 | |
| Depreciation & Amortization | 0.00 | 0.00 | 0.00 | |
| EBITDA | -8↓79.7% | -4↓15.1% | -4 | |
| EBIT | -8↓79.7% | -4↓15.1% | -4 | |
| Interest & Other Income | ||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | -1↑95.5% | -26↓1300300.0% | 0.00 | |
| Income Before Tax | -9↑70.4% | -30↓703.3% | -4 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||
| Net Income from Continuing Operations | -9↑70.4% | -30↓703.3% | -4 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | |
| Net Income | -9↑70.4% | -30↓703.3% | -4 | |
| Bottom-Line Net Income | -9↑70.4% | -30↓703.3% | -4 | |
| EPS (Basic) | -0.19↓18.8% | -0.16↓700.0% | -0.02 | |
| EPS (Diluted) | -0.19↓18.8% | -0.16↓700.0% | -0.02 | |
| Weighted Average Shares | 47↓75.0% | 189↑0.0% | 189 | |
| Weighted Average Diluted Shares | 47↓75.0% | 189↑0.0% | 189 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.